Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 4 October 2017, 09:49 HKT/SGT
Share:
    

Source: Eisai
Eisai and Biotoscana Sign Exclusive Licensing Agreement for Latin America

TOKYO, Oct 4, 2017 - (JCN Newswire) - Eisai Co., Ltd. announced today that its U.S. subsidiary, Eisai Inc., has signed an exclusive licensing agreement with Grupo Biotoscana for Eisai's oncology and neurology products in Latin America.

Under the terms of the agreement, Eisai Inc. grants Biotoscana an exclusive license to seek regulatory approvals and commercialize the anticancer agents Halaven and Lenvima, as well as antiepileptic agents Fycompa and Inovelon in Latin America. In Mexico, however, Eisai will retain the rights to, and conduct all activities for, Halaven and Lenvima. Eisai Inc. will supply Biotoscana with the products, for which it will receive compensation, and is also entitled to a one-time payment as well as milestone payments.

Biotoscana is a pharmaceutical company operating out of 10 countries in Latin America, where it is developing a strong portfolio that includes oncology products. As a result of granting Biotoscana these licenses, Eisai can swiftly expand access in Latin American markets for its innovative new drugs, and further contribute to patients in Latin America.

Eisai positions oncology and neurology as key therapeutic areas. By accelerating the development of its innovative new drugs in these areas and pursuing optimal business models to match regional characteristics, Eisai seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients and their families all over the world.

About Grupo Biotoscana Grupo

Biotoscana is a biopharmaceutical group that operates in the fast-growing Latin American region and focuses on rapidly growing market segments such as infectious diseases, oncology and onco-hematology, special treatments, immunology and inflammation and orphan/rare diseases, among others. Grupo Biotoscana is currently present throughout 10 Latin American countries (Argentina, Uruguay, Ecuador, Colombia, Chile, Paraguay, Brazil, Peru, Bolivia, and Mexico) where it operates under its companies Biotoscana, United Medical and LKM. Grupo Biotoscana's strong portfolio combines world-class licenses and proprietary products.


About Eisai

Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


Oct 4, 2017 09:49 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: HealthCare
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2017 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Dec 8, 2017 13:57 HKT/SGT
Eisai: Updated Analysis of Phase Ib/II Study of Eribulin and Pembrolizumab Combination Regimen
Dec 6, 2017 16:31 HKT/SGT
Eisai Submits Application for Expanded Indication Covering Hepatocellular Carcinoma for Anticancer Agent Lenvima in Taiwan
Nov 30, 2017 08:41 HKT/SGT
Eisai's Resubmitted NDA for Anticancer Agent Halaven Accepted in China
Nov 24, 2017 14:07 HKT/SGT
Eisai to Present Latest Data on Perampanel and Rufinamide at 71st American Epilepsy Society Annual Meeting
Nov 20, 2017 14:50 HKT/SGT
Eisai Receives IT Business Award for Medication Administration Support Device e-OKUSURI-SAN
Nov 20, 2017 14:28 HKT/SGT
Eisai: Antiepileptic Drug Fycompa Regularly Available Again in Germany from December
Nov 6, 2017 19:37 HKT/SGT
New Data From Long-Term Extension of Phase 1B Study of Investigational Alzheimer's Disease Treatment Aducanumab Presented at 10th Clinical Trials on Alzheimer's Disease
Oct 31, 2017 12:05 HKT/SGT
Eisai's New Drug Application of Anticancer Agent Lenvatinib for Hepatocellular Carcinoma Accepted in China
Oct 31, 2017 10:27 HKT/SGT
Eisai to Present Latest Data at 10th Clinical Trials on Alzheimer's Diesase
Oct 24, 2017 10:08 HKT/SGT
Biogen and Eisai Expand Existing Collaboration Agreement to Develop and Commercialize Investigational Alzheimer's Disease Treatments Including Phase 3 Aducanumab
More news >>
 News Alerts
Copyright © 2017 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: